indapamide has been researched along with Chronic Kidney Failure in 8 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long-term effects of indapamide or hydrochlorothiazide on blood pressure and renal function were examined in patients with impaired renal function and moderate hypertension." | 9.08 | Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1995) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood pressure and renal function were examined in patients with impaired renal function and moderate hypertension." | 5.08 | Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1995) |
| "The results of a study conducted using a new loop diuretic, Azosemide, on a group of 45 patients suffering from hypertension and oedema are reported." | 3.67 | [Diuretic and antihypertensive activity of azosemide]. ( Bartoli, E; Branca, GF; Faedda, R; Satta, A, 1985) |
| " The results obtained from single-blind, placebo-controlled studies indicate that indapamide is a safe and effective agent to use in lowering the blood pressure of hypertensive patients with normal renal function, those with various degrees of renal impairment, and those who are undergoing long-term maintenance hemodialysis." | 2.65 | Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. ( Acchiardo, SR; Skoutakis, VA, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, MG | 1 |
| Perkovic, V | 1 |
| Chalmers, J | 2 |
| Woodward, M | 2 |
| Li, Q | 2 |
| Cooper, ME | 1 |
| Hamet, P | 2 |
| Harrap, S | 2 |
| Heller, S | 1 |
| MacMahon, S | 1 |
| Mancia, G | 1 |
| Marre, M | 2 |
| Matthews, D | 1 |
| Neal, B | 1 |
| Poulter, N | 1 |
| Rodgers, A | 1 |
| Williams, B | 1 |
| Zoungas, S | 2 |
| Mohammedi, K | 1 |
| Patel, A | 1 |
| Acchiardo, SR | 1 |
| Skoutakis, VA | 1 |
| Madkour, H | 1 |
| Gadallah, M | 1 |
| Riveline, B | 1 |
| Plante, GE | 1 |
| Massry, SG | 1 |
| Meyrier, A | 1 |
| Condamin, MC | 1 |
| Leenen, FH | 1 |
| Smith, DL | 1 |
| Farkas, RM | 1 |
| Boer, WH | 1 |
| Reeves, RA | 1 |
| Marquez-Julio, A | 1 |
| Satta, A | 1 |
| Faedda, R | 1 |
| Branca, GF | 1 |
| Bartoli, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286] | 8,494 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for indapamide and Chronic Kidney Failure
| Article | Year |
|---|---|
What matters in ADVANCE and ADVANCE-ON.
Topics: Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabete | 2012 |
5 trials available for indapamide and Chronic Kidney Failure
| Article | Year |
|---|---|
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin | 2016 |
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea | 2016 |
Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment.
Topics: Aldosterone; Blood Pressure; Body Weight; Diuretics; Hemodynamics; Humans; Hypertension; Indapamide; | 1983 |
Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension.
Topics: Body Weight; Creatinine; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertensi | 1995 |
Cardiovascular effects of indapamide in hypertensive patients with or without renal failure. A dose-response curve.
Topics: Cardiovascular System; Diuretics; Dose-Response Relationship, Drug; Drug Evaluation; Echocardiograph | 1988 |
2 other studies available for indapamide and Chronic Kidney Failure
| Article | Year |
|---|---|
[Antihypertensive action of indapamide in hypertension of chronic renal failure].
Topics: Ambulatory Care; Antihypertensive Agents; Benzothiadiazines; Diuretics; Drug Evaluation; Female; Hum | 1994 |
[Diuretic and antihypertensive activity of azosemide].
Topics: Body Weight; Diuresis; Edema; Humans; Hypertension; Indapamide; Kidney Failure, Chronic; Sulfanilami | 1985 |